Myomics’ robotic MyoForce Analysis System™ (MFAS™) uses contractile three-dimensional human or mouse muscle tissue analogs to rapidly screen drugs in vitro for enhanced muscle strength, reduced fatigue, and injury prevention. Myomics takes a fundamentally different approach to drug screening than high throughput screening (HTS) companies. Most competitors aim HTS at a single targeted pathway. Hundreds of positive hits are obtained and it is costly and time consuming to take these into follow-on in vivo studies.
Myomics' high content screening technology is based on muscle function rather than single pathways, and can better predict which compounds are most likely to succeed in animal and human studies. It is thus an ideal secondary screen on HTS hits, reducing time and cost six- to ten-fold. Also, screening with diseased human muscle tissue gives greater confidence before moving into clinical trials.
MFAS™ Screening Benefits
